HK1107026A1 - Treatment of short bowel syndrome patients with colon-in-continuity - Google Patents

Treatment of short bowel syndrome patients with colon-in-continuity

Info

Publication number
HK1107026A1
HK1107026A1 HK08100908.3A HK08100908A HK1107026A1 HK 1107026 A1 HK1107026 A1 HK 1107026A1 HK 08100908 A HK08100908 A HK 08100908A HK 1107026 A1 HK1107026 A1 HK 1107026A1
Authority
HK
Hong Kong
Prior art keywords
colon
continuity
treatment
bowel syndrome
short bowel
Prior art date
Application number
HK08100908.3A
Other languages
English (en)
Inventor
Elizabeth L Sanguinetti
Thomas B Marriott
Jennifer Lopansri
Consuelo Maria Blosch
Original Assignee
Nps Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36319726&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1107026(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nps Pharma Inc filed Critical Nps Pharma Inc
Publication of HK1107026A1 publication Critical patent/HK1107026A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/42—Detecting, measuring or recording for evaluating the gastrointestinal, the endocrine or the exocrine systems
    • A61B5/4222—Evaluating particular parts, e.g. particular organs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Physiology (AREA)
  • Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
HK08100908.3A 2004-11-01 2008-01-24 Treatment of short bowel syndrome patients with colon-in-continuity HK1107026A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62323304P 2004-11-01 2004-11-01
PCT/US2005/039222 WO2006050244A2 (en) 2004-11-01 2005-11-01 Treatment of short bowel syndrome patients with colon-in-continuity

Publications (1)

Publication Number Publication Date
HK1107026A1 true HK1107026A1 (en) 2008-03-28

Family

ID=36319726

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08100908.3A HK1107026A1 (en) 2004-11-01 2008-01-24 Treatment of short bowel syndrome patients with colon-in-continuity

Country Status (8)

Country Link
US (70) US7847061B2 (de)
EP (1) EP1809318B1 (de)
JP (1) JP5197012B2 (de)
CA (1) CA2585482C (de)
DK (1) DK1809318T3 (de)
ES (1) ES2427150T3 (de)
HK (1) HK1107026A1 (de)
WO (1) WO2006050244A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184201B1 (en) * 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
US5834428A (en) * 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
JP5197012B2 (ja) * 2004-11-01 2013-05-15 エヌピーエス ファーマシューティカルズ インコーポレイテッド 大腸連続性を伴う短腸症候群患者の治療
ATE498631T1 (de) * 2005-05-04 2011-03-15 Zealand Pharma As Glucagon-like-peptide-2- (glp-2-) analoga
CN101573376B (zh) 2006-11-08 2013-11-06 西兰制药公司 选择性胰高血糖素样肽-2（glp-2）类似物
US20130157954A1 (en) * 2010-05-11 2013-06-20 Nps Pharmaceuticals, Inc. Methods for treatment or prophylaxis of kidney or liver dysfunction
CN104540850B (zh) 2012-05-03 2018-05-18 西兰制药公司 胰高血糖素样肽2(glp-2)类似物
US20170063005A1 (en) * 2015-08-27 2017-03-02 Tyco Electronics Corporation Array connector and method of manufacturing the same
TWI591177B (zh) 2016-10-27 2017-07-11 中化合成生技股份有限公司 一種胰高血糖素胜肽－２（ｇｌｐ－２）類似物的製備方法
RU2753193C2 (ru) 2016-12-09 2021-08-12 Зилэнд Фарма А/С Ацилированные двойные агонисты glp-1/glp-2
WO2018142363A1 (en) * 2017-02-06 2018-08-09 Orbicular Pharmaceutical Technologies Private Limited Ready to use compositions of glp-2 analogues through self-administrable devices
CN111032072A (zh) * 2017-06-16 2020-04-17 西兰制药公司 用于施用胰高血糖素样肽2（glp-2）类似物的剂量方案
US10105588B1 (en) 2017-09-26 2018-10-23 Chasen Massey Snowboard binding with adjustment memory
WO2019090209A1 (en) * 2017-11-06 2019-05-09 Shire-Nps Pharmaceuticals, Inc. Glp-2 analogs and peptibodies for administration before during, or after surgery
CN112840211A (zh) * 2018-08-27 2021-05-25 南特生物公司 Rp182组合物及方法
KR20210126088A (ko) 2019-02-11 2021-10-19 옵코 바이오로직스 리미티드 지속성 glp-2 유사체
IL298964A (en) 2020-06-09 2023-02-01 Vectivbio Ag Manufacture, formulation and dosage of APRAGLUTIDE

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184201B1 (en) * 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
US5789379A (en) 1995-04-14 1998-08-04 Allelix Biopharmaceutical Inc. Glucagon-like peptide-2 analogs
CA2221136A1 (en) 1995-06-06 1996-12-12 Kimberly-Clark Worldwide, Inc. Microporous film containing a microbial adsorbent
EP1231219B1 (de) 1996-04-12 2010-08-25 1149336 Ontario Inc. Dem Glukagon ähnliches Peptid-2
EG21623A (en) 1996-04-16 2001-12-31 Procter & Gamble Mid-chain branced surfactants
US5994500A (en) 1996-07-19 1999-11-30 1149336 Ontario Inc. Antagonists of intestinotrophic GLP-2 peptides
US6077949A (en) 1996-12-13 2000-06-20 Allelix Biopharmaceuticals, Inc. Cloned glucagon-like peptide 2 receptors
JP4699576B2 (ja) 1997-05-16 2011-06-15 １１４９３３６ オンタリオ インコーポレーテッド 胃腸管上部の機能を強化する方法
JP2002504527A (ja) 1998-02-27 2002-02-12 ノボ ノルディスク アクティーゼルスカブ 部分的に組織化したミセル様凝集物を形成する２５％を越えるヘリックス成分を有するｇｌｐ−２誘導体
GB9930882D0 (en) 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
AU2002233089B2 (en) 2001-02-16 2005-12-22 Conjuchem Biotechnologies Inc. Long lasting glucagon-like peptide 2 (GLP-2) for the treatment of gastrointestinal diseases and disorders
US7411039B2 (en) 2002-10-14 2008-08-12 Novo Nordisk A/S GLP-2 compounds, formulations, and uses thereof
WO2004085471A2 (en) 2003-03-24 2004-10-07 Novo Nordisk A/S Glp-2 derivatives
JP5197012B2 (ja) * 2004-11-01 2013-05-15 エヌピーエス ファーマシューティカルズ インコーポレイテッド 大腸連続性を伴う短腸症候群患者の治療

Also Published As

Publication number Publication date
WO2006050244A3 (en) 2006-09-08
US20190262428A1 (en) 2019-08-29
US20200376085A1 (en) 2020-12-03
US20200129593A1 (en) 2020-04-30
US20200397866A1 (en) 2020-12-24
US20170020969A1 (en) 2017-01-26
US20210236603A1 (en) 2021-08-05
US20180264087A1 (en) 2018-09-20
CA2585482C (en) 2018-01-02
US20170020971A1 (en) 2017-01-26
US20170028026A1 (en) 2017-02-02
US9968657B2 (en) 2018-05-15
US20170020979A1 (en) 2017-01-26
EP1809318A2 (de) 2007-07-25
DK1809318T3 (da) 2013-09-08
US20170020983A1 (en) 2017-01-26
US9968655B2 (en) 2018-05-15
US20200147182A1 (en) 2020-05-14
US20170020982A1 (en) 2017-01-26
US20170020974A1 (en) 2017-01-26
US20170020986A1 (en) 2017-01-26
US9974837B2 (en) 2018-05-22
US9545435B1 (en) 2017-01-17
US20170020988A1 (en) 2017-01-26
US20170020980A1 (en) 2017-01-26
US20200376084A1 (en) 2020-12-03
ES2427150T3 (es) 2013-10-29
US20170020978A1 (en) 2017-01-26
US20210213105A1 (en) 2021-07-15
US20200138910A1 (en) 2020-05-07
US20170020976A1 (en) 2017-01-26
US9974836B2 (en) 2018-05-22
US9987335B2 (en) 2018-06-05
US9572867B2 (en) 2017-02-21
US20060135424A1 (en) 2006-06-22
US9545434B2 (en) 2017-01-17
US9060992B2 (en) 2015-06-23
US7847061B2 (en) 2010-12-07
US20200405818A1 (en) 2020-12-31
US20190275111A1 (en) 2019-09-12
WO2006050244A2 (en) 2006-05-11
US20190381146A1 (en) 2019-12-19
EP1809318B1 (de) 2013-06-12
JP5197012B2 (ja) 2013-05-15
US20170020967A1 (en) 2017-01-26
US20200016241A1 (en) 2020-01-16
US20170020987A1 (en) 2017-01-26
US9987334B2 (en) 2018-06-05
US20200206316A1 (en) 2020-07-02
US9592273B2 (en) 2017-03-14
JP2008518941A (ja) 2008-06-05
US20170020972A1 (en) 2017-01-26
US20170020973A1 (en) 2017-01-26
US20170020966A1 (en) 2017-01-26
US20210000923A1 (en) 2021-01-07
US20170020984A1 (en) 2017-01-26
US20170028025A1 (en) 2017-02-02
US20200390862A1 (en) 2020-12-17
CA2585482A1 (en) 2006-05-11
US20170028024A1 (en) 2017-02-02
US9981016B2 (en) 2018-05-29
US20170028028A1 (en) 2017-02-02
US20150290296A1 (en) 2015-10-15
US20210015904A1 (en) 2021-01-21
US20190275113A1 (en) 2019-09-12
US20170020970A1 (en) 2017-01-26
US20190298807A1 (en) 2019-10-03
US20170028030A1 (en) 2017-02-02
US20170020989A1 (en) 2017-01-26
US20190351027A1 (en) 2019-11-21
US20200164041A1 (en) 2020-05-28
US9981015B2 (en) 2018-05-29
US20170028029A1 (en) 2017-02-02
US20210213106A1 (en) 2021-07-15
US9539310B1 (en) 2017-01-10
US9974835B2 (en) 2018-05-22
US20200129594A1 (en) 2020-04-30
US20190307852A1 (en) 2019-10-10
US20170020985A1 (en) 2017-01-26
US9968656B2 (en) 2018-05-15
US20210015903A1 (en) 2021-01-21
US20210038695A1 (en) 2021-02-11
US20170020965A1 (en) 2017-01-26
US20200147181A1 (en) 2020-05-14
US20110172152A1 (en) 2011-07-14
US9999656B2 (en) 2018-06-19
US9974838B2 (en) 2018-05-22
US20190269760A1 (en) 2019-09-05
US20200164043A1 (en) 2020-05-28
US20170028027A1 (en) 2017-02-02
US20170020977A1 (en) 2017-01-26
US20170020975A1 (en) 2017-01-26
US20190298806A1 (en) 2019-10-03
US9592274B2 (en) 2017-03-14
US9555079B1 (en) 2017-01-31
US20170020968A1 (en) 2017-01-26
US20200164040A1 (en) 2020-05-28
US20190262427A1 (en) 2019-08-29
US9968658B2 (en) 2018-05-15
US20190275112A1 (en) 2019-09-12
US20210077586A1 (en) 2021-03-18
US9993528B2 (en) 2018-06-12
US9981014B2 (en) 2018-05-29
US20170020981A1 (en) 2017-01-26

Similar Documents

Publication Publication Date Title
HK1107026A1 (en) Treatment of short bowel syndrome patients with colon-in-continuity
EP1827338A4 (de) Behandlung analer inkontinenz
EP1731113A4 (de) Medizinischs behandlungskit
EP1755584A4 (de) Behandlung von myopie
GB0403969D0 (en) Tissue treatment device
EP1738735A4 (de) Medizinisches bett
EP1789047A4 (de) Behandlung von erkrankungen mittels nalmefen und seiner analoga
IL178827A0 (en) Use of reboxetine for the treatment of pain
EP1755635A4 (de) Behandlung von entzündlicher atemwegserkrankung
GB0415181D0 (en) Compounds for use in the treatment of infection
EP1793813A4 (de) Behandlung von adhd
GB0426196D0 (en) Methods of treatment
EP1767210A4 (de) Medizinsiche verwendung von paeoniflorin
GB0426141D0 (en) Treatment
GB0701549D0 (en) Skin treatment
GB0425854D0 (en) Therapeutic treatment
GB0423173D0 (en) Treatment of diabetes
IL180709A0 (en) Treatment of tumours
ZA200704046B (en) Treatment of burns
GB0419703D0 (en) Medical treatment
GB0401807D0 (en) Medical treatment
GB0415318D0 (en) Medical treatment
GB0401792D0 (en) Medical treatment
GB0408752D0 (en) Therapeutic treatment
HU0400952D0 (en) Treatment of anus-cancer

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20231027